GlaxosmithKline (GSK) has agreed to continue its collaboration with
CytoKinetics, which focused towards the mitotic kinesin,
centromere-associated protein E (CENP-E) that has evolved to become
a novel and viable drug target.
Astex has announced that the United States Food and Drug
Administration (FDA) has approved its Investigational New Drug
(IND) application for the clinical development of its cell cycle
inhibitor, AT7519, for the treatment of cancer.
Cyclacel has received a US patent that covers a novel series of
pyrimidine small molecules shown to inhibit the progress of cells
through the cancer cell cycle. The patented compounds may be useful
as therapeutics for cancer, inflammatory...